NCT00664378View on ClinicalTrials.gov

Efficacy Study of CYT997 in Multiple Myeloma

PHASE2TerminatedINTERVENTIONAL

Enrollment

5

Participants

Timeline

Start Date

January 31, 2008

Primary Completion Date

February 28, 2011

Study Completion Date

February 28, 2011

Conditions

Relapsed and Refractory Multiple Myeloma

Interventions

DRUG

CYT997

Intravenous infusion (24h); 202mg/m2 on days 1 and 8 of a 21 day cycle

Trial Locations (1)

3004

The Alfred Hospital, Melbourne

Sponsors

Lead Sponsor

Gilead Sciences

All Listed Sponsors

lead

Gilead Sciences

INDUSTRY